Skip to main content

Table 2 Hazard ratios of overall mortality and distant disease according to tertiles of serum 25(OH)D

From: Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study

  Serum 25(OH)D
  Continuous Categorized
  per 10 nmol/L decrement < 35 nmol/L 35-55 nmol/L ≥ 55 nmol/L
Outcome No.
(events)
HR 95% CI P trend a No.
(events)
HR 95% CI No.
(events)
HR 95% CI No.
(events)
HR 95% CI
Overall mortality              
   Crude†b 1,295 (183) 1.11 1.03 to 1.18 0.009 432 (87) 1.96 1.32 to 2.90 407 (46) 0.94 0.62 to 1.44 456 (50) 1.00 -
   Multivariate‡c 1,265 (174) 1.08 1.00 to 1.17 0.07 422 (82) 1.55 1.00 to 2.39 397 (44) 0.72 0.45 to 1.17 446 (48) 1.00 -
Distant disease              
   Crudeb 1,088 (137) 1.12 1.03 to 1.21 0.01 341 (64) 2.09 1.31 to 3.30 347 (37) 1.19 0.73 to 1.93 400 (36) 1.00 -
   Multivariatec 1,074 (135) 1.14 1.05 to 1.24 0.006 338 (63) 2.09 1.29 to 3.41 342 (37) 1.16 0.70 to 1.94 394 (35) 1.00 -
  1. 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; HR, hazard ratio.
  2. a Calculated by using serum 25(OH)D as a continuous variable.
  3. b Stratified by age at diagnosis and season.
  4. c Stratified by age at diagnosis and season, adjusted for tumor size, nodal status, metastases, tumor grade, estrogen/progesterone receptor status, diabetes, mode of detection; due to missing covariate values, 30 observations were not included in the multivariate model.